Conivaptan and Belumosudil: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 15, 2026 · Source data updated Jul 11, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Conivaptan
Belumosudil
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Let's talk about taking these two together. Conivaptan blocks a liver enzyme called CYP3A, and your body uses that same enzyme to break down belumosudil (Rezurock). When the enzyme is blocked, belumosudil can build up higher than intended, which may raise your chance of side effects.
Because of this, these two are generally not used at the same time. This concern is based mostly on how the drugs work rather than on direct studies, but the effect can be strong, so it's taken seriously. The good news is your care team can manage this by planning the timing and watching you closely. Please check with your pharmacist or doctor before combining them.
Effect: Increased belumosudil exposure. Conivaptan is a strong CYP3A inhibitor, and belumosudil is a CYP3A substrate, so inhibition of CYP3A-mediated metabolism raises belumosudil AUC/Cmax and side-effect risk.
- Direction: Increased substrate exposure (belumosudil is not a prodrug; higher levels = more effect/toxicity).
- Magnitude: Not quantified for belumosudil; conivaptan raised AUC of midazolam, simvastatin, and amlodipine.
- Onset: Unspecified. Evidence: Theoretical.
- Management: Avoid coadministration. Do not initiate the CYP3A substrate sooner than 1 week after completing conivaptan.
What happens
Increased CYP3A substrate exposure
Interaction Deep Dive
Do not administer conivaptan (a potent CYP3A inhibitor) alongside medications that depend chiefly on CYP3A-mediated metabolism for their clearance, since doing so can raise the exposure of the CYP3A substrate. The AUC of the CYP3A substrates midazolam, simvastatin, and amLODIPine was elevated by conivaptan. A minimum of 1 week should elapse after conivaptan therapy ends before starting the CYP3A substrate1.
Why it happens (mechanism)
Inhibition of CYP3A-mediated substrate metabolism by conivaptan
How to manage this interaction
Here is how a care team typically handles this combination:
- Avoid using them together when possible, since conivaptan can raise belumosudil levels.
- Timing matters: belumosudil is generally not started until at least 1 week after conivaptan is finished.
- If both are somehow needed, your team may monitor you more closely and adjust as needed.
What you should do: keep taking your medications as prescribed and do not stop or change anything on your own. Bring both to the attention of your pharmacist or prescriber so they can plan the timing and watch for side effects.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
3 reports — tap to read
a) When administered as a potent CYP3A inhibitor, conivaptan 40 mg/day IV raised the AUC of midazolam, a CYP3A substrate, by roughly 100% following a 1 mg IV dose and by 200% following a 2 mg oral dose 1.
b) Conivaptan 30 mg/day IV produced a threefold increase in the AUC of simvastatin, a CYP3A substrate 1.
c) Conivaptan 40 mg given orally twice daily doubled both the AUC and the half-life of amLODIPine, a CYP3A substrate 1.
Common questions
Can I take Conivaptan and Belumosudil together?
Conivaptan can raise belumosudil levels by blocking its breakdown, so these are generally avoided together and belumosudil should not be started until at least a week after conivaptan ends. Ask your pharmacist or doctor before combining them. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Conivaptan and Belumosudil interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Conivaptan and Belumosudil interaction managed?
Here is how a care team typically handles this combination: Avoid using them together when possible, since conivaptan can raise belumosudil levels. Timing matters: belumosudil is generally not started until at least 1 week after conivaptan is finished. If both are somehow needed, your team may monitor you more closely and adjust as needed. What you should do: keep taking your medications as prescr… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Conivaptan or Belumosudil need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: VAPRISOL(R) intravenous injection, conivaptan HCl intravenous injection. Cumberland Pharmaceuticals Inc. (per manufacturer), Nashville, TN, 2014.
Keep reading about Conivaptan
Keep reading about Belumosudil
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist